RASAL2 mediated PPP1CA–p38 MAPK–SMAD2/3 signaling promotes cancer stemness and immune evasion in immune-desert gastric cancer

Gastric cancer, commonly known as stomach cancer, remains one of the most deadly diseases worldwide, often because it is difficult to treat once it has spread. A major hurdle in modern medicine is the failure of immunotherapy, a treatment designed to wake up the body's own immune system to fight cancer. For some patients, these drugs work wonders, but for many others, the treatment does nothing. The reason often lies in the landscape of the tumor itself. Some tumors are like bustling cities, filled with immune cells ready to attack; these are called "immune-inflamed" and usually respond well to therapy. Others are like barren deserts, completely empty of these helpful soldiers; these are "immune-desert" tumors, and they are notoriously resistant to treatment. Understanding why some tumors become these immune deserts is one of the most critical questions in cancer research today.

A team of researchers from Fujian Medical University Union Hospital and other institutions has now uncovered a specific biological mechanism that turns a stomach tumor into an immune desert. By studying a large collection of patient samples using advanced genetic mapping and laboratory experiments, they identified a single protein, called RASAL2, that acts as a master switch. When this protein is active, it does two damaging things at once: it helps the cancer cells become more stubborn and resistant to drugs, and it actively builds a wall that keeps the immune system's attack force out. The study, published recently, suggests that by turning off this switch, doctors might be able to make these resistant tumors vulnerable again.

The researchers began by looking at 105 stomach tumor samples from patients, using a combination of genetic sequencing and microscopic imaging to map the cellular environment. They sorted these tumors into two distinct groups based on what they saw inside. The first group was the immune-inflamed type, packed with CD8+ T cells, which are the immune system's primary soldiers designed to hunt down and destroy cancer. The second group was the immune-desert type, where these soldiers were almost entirely absent. When the team analyzed the genetic activity of the cancer cells in these two groups, they found a striking difference. The desert tumors were not just empty; they were actively running a different set of instructions. These instructions promoted a state of "stemness," a biological trait that allows cancer cells to act like seeds, capable of regenerating the entire tumor and surviving chemotherapy.

Among the many genes active in these desert tumors, one stood out: RASAL2. The researchers found that this gene was turned on much higher in the immune-desert tumors than in the inflamed ones. To prove that RASAL2 was the culprit, they performed experiments in the lab and in mice. When they reduced the amount of RASAL2 in cancer cells, the cells lost their "stem-like" qualities and became much more sensitive to standard chemotherapy drugs like oxaliplatin. Conversely, when they increased RASAL2, the cells became tougher and harder to kill. In mice that developed stomach tumors naturally, removing the RASAL2 gene led to significantly smaller tumors with fewer cancer stem cells. This confirmed that RASAL2 is a key driver of the cancer's ability to survive and regenerate.

But how does a protein inside a cancer cell keep the immune system out? The researchers traced the path of signals inside the cell to find the answer. They discovered that RASAL2 binds to another protein called PPP1CA. Normally, PPP1CA acts as a brake on a specific signaling pathway involving p38 MAPK and SMAD2/3. However, RASAL2 grabs onto PPP1CA and stops it from working. With the brake released, the p38 MAPK and SMAD2/3 pathway goes into overdrive. This hyperactive pathway does two things. First, it tells the cancer cell to maintain its stem-like state, making it resistant to treatment. Second, it triggers a chain reaction that shuts down the signals the tumor needs to call for help from the immune system.

Specifically, the study showed that when RASAL2 is active, the tumor suppresses the production of chemical signals called CXCL9 and CXCL10. These signals are like emergency flares that normally attract CD8+ T cells to the tumor site. Without them, the T cells never arrive, leaving the tumor in a state of isolation. Furthermore, the overactive pathway forces the cancer cell to produce a protein called PD-L1 on its surface. PD-L1 acts as a disguise, allowing the cancer cell to trick any immune cells that do manage to get close, telling them to stand down and not attack. The researchers identified that this entire process is controlled by a transcription factor called BACH1, which is turned on by the SMAD2/3 pathway and directly instructs the cell to make PD-L1.

To test if this discovery could lead to better treatments, the researchers combined their findings with existing therapies. They treated mice with tumors that had high levels of RASAL2 using a combination of chemotherapy and a drug that blocks the PD-L1 disguise. In mice where RASAL2 was still active, the treatment had limited success. However, when they first reduced the levels of RASAL2, the combination therapy worked remarkably well, shrinking the tumors significantly more than either treatment alone. This happened because lowering RASAL2 removed the barrier that kept the immune cells away and stopped the cancer from hiding, allowing the immune system and the chemotherapy to work together effectively.

The study also clarified what is not happening. The researchers found that RASAL2 does not work through the most common cancer signaling pathway known as RAF-MEK-ERK. Instead, it operates through this specific, previously unknown interaction with PPP1CA. However, the study did show that RASAL2 does alter the secretion of initial immune signals; specifically, it suppresses the secretion of IFN-γ, a key cytokine that helps initiate the immune response. The findings suggest that RASAL2 is a central coordinator that links the cancer's ability to regenerate with its ability to hide from the immune system.

This work provides a clear biological explanation for why some stomach cancers are so difficult to treat. It shows that the immune desert is not a passive state of neglect but an active construction built by the tumor itself. By identifying RASAL2 as the switch that controls this construction, the study offers a new target for future therapies. If doctors can find a way to turn off this switch, they may be able to transform a barren, resistant tumor into one that is open to attack, potentially turning a deadly disease into a manageable one for many more patients. The researchers emphasize that while these results are promising, larger clinical studies will be needed to confirm how well targeting this pathway works in people.